Zhitong Financial App News, Yasheng Pharmaceutical (06855) announced that the company's original Class 1 new drug, Rysentol® (generic name: risatocla, R&D code: APG-2575), was included in the “Breakthrough Treatment Varieties” list by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Breakthrough treatment varieties are usually awarded to treat diseases that seriously endanger life or seriously affect quality of life, and there is no effective prevention method, or innovative drugs or improved new drugs that have sufficient evidence of obvious clinical advantages compared to existing treatments. For drugs included in breakthrough therapeutic categories, CDE will prioritize the allocation of resources to communicate, strengthen guidance and promote the drug development process; applicants who have been assessed to meet the relevant conditions can also submit conditional approval applications and priority review and approval applications when applying for a product marketing license. The review policy for breakthrough therapeutic varieties will accelerate the development and marketing of innovative or improved drugs with significant clinical value and urgent clinical needs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.